Pleomorphic Xanthoastrocytoma
9
3
6
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
66.7%
-19.9% vs benchmark
11%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (9)
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Social Determinants of Health in Glioblastoma Population
Pediatric Long-Term Follow-up and Rollover Study
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas